[Current situation and the latest progress in the treatment of pyoderma gangrenosum].

Pyoderma gangrenosum (PG) is a rare chronic inflammatory non-infectious skin dermatosis, and there is no clear treatment guideline for this disease at home and abroad. There are a variety of clinical treatment methods for PG, including local therapy and systemic application of glucocorticoids, immunosuppressants, intravenous immuno- globulin, and biologics. Glucocorticoids are the first-line drugs commonly used in clinical practice, and immunosuppressants can be used alone or in combination with glucocorticoids. In recent years, more and more evidence has shown that biologics are a new trend in the treatment of PG, mainly including tumor necrosis factor α inhibitors, interleukin-1 (IL-1) inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, rituximab, and small molecular inhibitors. This article summarizes the current status and latest progress in the treatment of PG, hoping to provide clinicians with ideas for the treatment of PG.坏疽性脓皮病（PG）是一种少见的慢性炎症性非感染性皮肤病，现国内外没有明确的针对该病的治疗指南。临床上针对PG有多种治疗方法，包括局部治疗以及系统应用糖皮质激素、免疫抑制剂、静脉注射Ig及生物制剂等，其中，糖皮质激素为临床上常用的一线药物，免疫抑制剂可单独使用或联合糖皮质激素使用。近些年越来越多的证据表明生物制剂是治疗PG的新趋势，主要制剂包括肿瘤坏死因子α抑制剂、白细胞介素1（IL-1）抑制剂、IL-12/23抑制剂、IL-17抑制剂、利妥昔单抗及小分子抑制剂。该文针对PG的治疗现状及最新进展进行归纳总结，希望能为临床医师治疗PG提供思路。.